机构

• 上海药物研究所 [13]
• 合肥物质科学研究院 [11]
• 昆明动物研究所 [6]
• 沈阳自动化研究所 [5]
• 上海生物化学与细胞生... [2]
• 深圳先进技术研究院 [1]
• 更多

采集方式

• OAI收割 [41]
• iSwitch采集 [1]

内容类型

• 期刊论文 [36]
• 会议论文 [3]
• 学位论文 [3]

发表日期

• 2023 [1]
• 2022 [4]
• 2021 [3]
• 2020 [5]
• 2018 [4]
• 2017 [3]
• 更多

学科主题

• Microbiolo... [1]
• Oncology [1]

筛选

浏览/检索结果: 共42条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 期刊论文  OAI收割 BLOOD ADVANCES, 2023, 卷号: 7 作者:  Bachy, Emmanuel;  Savage, Kerry J.;  Huang, Huiqiang;  Kwong, Yok-Lam;  Gritti, Giuseppe   |  收藏  |  浏览/下载：16/0  |  提交时间：2023/11/10 The Prognostic Utility of F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2022, 卷号: 12 作者:  Li, Cong;  Yu, Haifeng;  Chen, Xi;  Han, Shuiyun;  Peng, Shuailing   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/12/23 diffuse large B cell lymphoma (DLBCL)  interim 18 F-FDG PET  prognosis  RCHOP  treatment response   Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma 期刊论文  OAI收割 BLOOD ADVANCES, 2022, 卷号: 6 作者:  Yang, Haiyan;  Xiang, Bing;  Song, Yuqin;  Zhang, Huilai;  Zhao, Weili   |  收藏  |  浏览/下载：24/0  |  提交时间：2022/12/23 Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文  OAI收割 CLINICAL CANCER RESEARCH, 2022, 卷号: 28 作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng   |  收藏  |  浏览/下载：51/0  |  提交时间：2022/05/05 High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文  OAI收割 BMC CANCER, 2022, 卷号: 22 作者:  Chen, Xi;  Kong, Haiying   |  收藏  |  浏览/下载：55/0  |  提交时间：2022/02/14 Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment   Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial 期刊论文  OAI收割 BLOOD, 2021, 卷号: 138 作者:  Ding, Kaiyang;  Liu, Hailing;  Yang, Haiyan;  Cao, Lei;  Zhao, Xiaoli   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/12/23 Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. 期刊论文  OAI收割 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng   |  收藏  |  浏览/下载：53/0  |  提交时间：2022/01/10 Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K-AKT-mTOR/JNK pathway 期刊论文  OAI收割 ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2021, 卷号: 53, 期号: 5, 页码: 575-583 作者:  Hu, Ke;  Li, Bo;  Ma, Ruye;  Yi, Hongfei;  Xu, Zhijian   |  收藏  |  浏览/下载：38/0  |  提交时间：2021/06/11 caspase  cell proliferation  cell cycle arrest  diffuse large B-cell lymphoma  PI3K-AKT-mTOR/JNK pathway   Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 卷号: 5 作者:     |  收藏  |  浏览/下载：44/0  |  提交时间：2020/11/30 Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients 期刊论文  OAI收割 TRANSLATIONAL CANCER RESEARCH, 2020, 卷号: 9 作者:  Li, Cong;  Lu, Fangxiao;  Lei, Tao;  Yu, Haifeng;  Yang, Haiyan   |  收藏  |  浏览/下载：21/0  |  提交时间：2020/11/30 B-cell lymphoma  chemotherapy  interstitial pneumonia (IP)  risk factor  rituximab